Skip to main content
THERACRYF PLC logo

THERACRYF PLC — Investor Relations & Filings

Ticker · TCF ISIN · GB00BSVYN304 LEI · 213800NO3E6TSTQO8K20 IL Professional, scientific and technical activities
Open in API
Filings indexed 361 across all filing types
Latest filing 2020-01-29 Regulatory Filings
Country GB United Kingdom
Listing IL TCF

About THERACRYF PLC

https://theracryf.com/

TheraCryf PLC is a clinical-stage therapeutics company focused on developing a new generation of innovative medicines for behavioural brain disorders and oncology. The company's research and development efforts are centered on sulforaphane-based compounds. Its primary therapeutic focus is on conditions such as opioid and alcohol abuse, binge eating disorder, anxiety, and fatigue. TheraCryf's business strategy is to generate compelling clinical data for its drug candidates with the goal of partnering its programs with larger pharmaceutical companies for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Price Monitoring Extension' for Evgen Pharma PLC. It is a standard market operational notice rather than a financial report, management update, or corporate action. As it does not fit into specific categories like dividends, share issues, or earnings, it falls under the general regulatory announcement category.
2020-01-29 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details a change in share ownership (voting rights) by a major shareholder (Richard Griffiths and controlled undertakings) in Evgen Pharma PLC. This fits the definition of a 'Major Shareholding Notification' (MRQ), which tracks significant changes in ownership levels.
2020-01-20 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details a change in share ownership (Amati AIM VCT plc's interest in Evgen Pharma PLC) and follows the regulatory format for major shareholding notifications as required by the FCA. This falls directly under the 'Major Shareholding Notification' category.
2020-01-17 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by Evgen Pharma PLC. It explicitly details a change in shareholding percentage by Amati AIM VCT plc, crossing a regulatory threshold. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2020-01-08 English
Investor presentation
Investor Presentation Classification · 95% confidence The document is an announcement from Evgen Pharma regarding an upcoming investor briefing/presentation. It is short (under 5,000 characters), serves as a notification of an event, and does not contain the actual presentation slides or the financial report itself. According to the 'Menu vs Meal' rule, this is an announcement of an event/report rather than the report itself, making it a Regulatory Filing (RNS) or a general announcement.
2019-12-17 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half year Report' for Evgen Pharma plc for the six months ended 30 September 2019. It contains detailed operational highlights, financial highlights (including specific loss and cash balance figures), and a comprehensive 'Chairman's and Chief Executive's Statement' discussing clinical trial results and future strategy. Since it provides substantive financial data and analysis for a period shorter than a full fiscal year, it qualifies as an Interim/Quarterly Report. H1 2019
2019-12-17 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.